Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase lb Study of Vyxeos® (Liposomal Daunorubicin and Cytarabine) in Combination With Clofarabine in Children With Relapsed/Refractory AML, ITCC-092

NCT07156435 is registered in ClinicalTrials.gov with Princess Maxima Center for Pediatric Oncology as lead sponsor.

NCT NCT07156435
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07156435 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase lb Study of Vyxeos® (Liposomal Daunorubicin and Cytarabine) in Combination With Clofarabine in Children With Relapsed/Refractory AML, ITCC-092
Lead sponsor
Princess Maxima Center for Pediatric Oncology
Phase
Phase 1
Overall status
Recruiting
Start date
November 6, 2020
Completion date
December 31, 2028
Enrollment
25 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

refractory pediatric aml, relapsed pediatric aml